Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran; Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Curr Probl Cardiol. 2022 Sep;47(9):100912. doi: 10.1016/j.cpcardiol.2021.100912. Epub 2021 May 29.
Despite many advances in the diagnosis and treatment of beta-thalassemia patients in recent years and their longevity and quality of life which has been greatly increased, many of these patients have other life-threatening risks. The prevalence of atrial fibrillation in beta-thalassemia patients and its related thromboembolism, stroke, and mortality have been increased in the last few years. Appropriate anticoagulant therapy may help to prevent the incidence or recurrence of thromboembolism. So far warfarin is the most widely used drug. Aspirin should use with caution in these patients because of its resistance to aspirin over time, which can increase the risk of thromboembolism. Direct oral anticoagulants (DOACs) are widely used to prevent embolism in coronary artery disease and venous thromboembolism, but their use in thalassemia patients is still very limited. More high-quality researches and clinical trials are needed to prove their effectiveness and safety for atrial fibrillation in beta-thalassemia patients.
尽管近年来β-地中海贫血患者的诊断和治疗取得了许多进展，他们的寿命和生活质量也大大提高，但许多患者仍面临其他危及生命的风险。近年来，β-地中海贫血患者心房颤动的患病率及其相关的血栓栓塞、中风和死亡率有所增加。适当的抗凝治疗可能有助于预防血栓栓塞的发生或复发。到目前为止，华法林是最广泛使用的药物。由于β-地中海贫血患者对阿司匹林的耐药性随时间推移而增加，因此阿司匹林的使用应谨慎，这会增加血栓栓塞的风险。直接口服抗凝剂（DOACs）广泛用于预防冠心病和静脉血栓栓塞的栓塞，但在β-地中海贫血患者中的使用仍然非常有限。需要更多高质量的研究和临床试验来证明它们在β-地中海贫血患者心房颤动中的有效性和安全性。
